[ad_1]
Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash.
Continue reading this article with a Barron’s subscription.
[ad_2]
Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion
Related Stories
Business
People are going to extreme lengths to stop themselves from being filmed through Meta’s ‘pervert glasses’ | Fortune
[ad_1] There’s an ongoing arms race to protect identities and privacy in the age of facial recognition, biometric…
Business
The Power of a ‘Warm Introduction’ Is Real. These Two Founders Are Working to Make Those Connections Happen.
[ad_1] Opinions expressed by Entrepreneur contributors are their own. Jake Fleshner and Michael Axman didn’t build The Nucleus Network to start another advisory…
Business
Google’s Gemini 3.7 Flash targets coding and agents with a 50% introductory price cut
[ad_1] Google is rolling out Gemini 3.7 Flash, a new version of its workhorse AI model that puts…
Business
On Our Island: Long Island business and community news roundup
[ad_1] Gatsby’s Game Café opens new spot at Samanea New York Courtesy of Samanea New York Lesso Mall…